AbbVie Inc. $ABBV Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 8.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,159 shares of the company’s stock after acquiring an additional 4,633 shares during the quarter. AbbVie comprises about 0.7% of GAMMA Investing LLC’s holdings, making the stock its 17th largest position. GAMMA Investing LLC’s holdings in AbbVie were worth $13,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. TD Capital Management LLC boosted its holdings in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares during the last quarter. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the 2nd quarter worth $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the second quarter valued at about $28,000. Finally, Financial Gravity Companies Inc. acquired a new stake in AbbVie during the second quarter worth about $36,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Up 1.9%

NYSE ABBV opened at $227.53 on Tuesday. The stock has a market cap of $402.14 billion, a P/E ratio of 172.37, a PEG ratio of 1.21 and a beta of 0.36. The company’s fifty day simple moving average is $227.20 and its 200-day simple moving average is $210.24. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 EPS. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research reports. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Wells Fargo & Company raised their price target on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Finally, Evercore ISI raised their target price on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $244.55.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.